abovementioned. Accordingly, our Directors are of the view that, it is expected that the downward fluctuations, if any, in number of SMILE surgeries conducted should stabilize gradually and will not have material adverse impact on our Group’s operation and financial performance.

Revenue generated from treatment for other eye problems had increased during the Track Record Period, from approximately HK\$36.3 million for the year ended 31 March 2019 to approximately HK\$36.8 million which for the year ended 31 March 2020 which was generally consistent with an increase in total number of patient visits, and then further increased to HK\$44.8 million for the year ended 31 March 2021 which was mainly due to the increase in revenue recorded for our standard cataract surgeries and laser procedures. Revenue generated from treatment for other eye problems had increased during the Track Record Period, from approximately HK\$12.3 million for the four months ended 31 July 2020 to approximately HK\$22.1 million for the four months ended 31 July 2021, which was mainly due to the increase in revenue recorded for each of our standard cataract surgeries, laser procedures, PPV surgeries and other treatments/surgeries. As the majority of our Medical Practitioners had been providing ophthalmic services under our brand ‘‘Clarity’’ for more than three years, we were able to build up our patient base by word-of-mouth referrals from existing patients and as a result, our Directors are of the view that it had contributed to the increase in revenue generated from treatments for other eye problems during the four months ended 31 July 2021.

Revenue generated from our consultation and examination service decreased from approximately HK\$9.2 million for the year ended 31 March 2019 to HK\$8.5 million for the year ended 31 March 2020 and had subsequently increased to HK\$9.1 million for the year ended 31 March 2021. Revenue generated from the sales of prescription remained relatively stable during the Track Record Period, which amounted to approximately HK\$6.3 million, HK\$6.2 million and HK\$6.9 million, respectively. Revenue generated from our consultation and examination service increased from approximately HK\$2.7 million for the four months ended 31 July 2020 to HK\$3.8 million for the four months ended 31 July 2021 which was mainly due to the growth of member of patient visits. Revenue generated from the sales of prescription increased by approximately HK\$0.8 million, or 39.4%, from approximately HK\$2.0 million for the four months ended 31 July 2020 to HK\$2.8 million for the four months ended 31 July 2021. The increase in revenue generated from sales of prescriptions and others was generally in line with our overall increase in consultation and examination services provided during the period.

The table below sets forth the breakdown of our revenue by refractive treatments for the Track Record Period:

For the year ended 31 March	For the four months ended 31 July
2019	2020	2021	2020	2021
HK$’000	%	HK$’000	%	HK$’000	%	HK$’000	%	HK$’000	%
(Unaudited)
Refractive treatments
(a) SMILE surgeries	97,822	63.2	112,424	67.4	100,104	61.9	29,786	61.4	26,964	54.6
(b) LASIK surgeries	2,735	1.8	2.808	1.7	3,654	2.3	1,067	2.3	1,119	2.2
(c) Multifocal IOL relpacements	49,227	31.8	43,343	26.0	49,064	30.3	14,962	30.9	17,833	35.6
(d) ICL imlpantations	4,970	3.2	8,226	4.9	8,846	5.5	2,660	5.4	3,760	7.6
Total	154,754	100.0	166,801	100.0	161,668	100.0	48,475	100.0	49,676	100.0